Qiagen and Bayer HealthCare have announced a collaboration agreement to develop and commercialize companion diagnostics paired with Bayer HealthCare drugs. The initial focus will be on enhancing the treatment of various solid tumors, according to a press release posted on the Qiagen website. Development of novel technologies for patient profiling that may result in innovative research-use-only products for exploratory and translational medicine are also part of the deal. Financial details were not disclosed.
The targeted companion diagnostics will be designed to run on the QIAsymphony family of automated instruments.
Noting the revolutionary advances that companion diagnostics affords in the treatment of cancer patients, Qiagen's Dr. Helge Lubenow, senior vice president, molecular diagnostics, said, "The first collaborations for Bayer HealthCare and Qiagen include companion diagnostics based on the identification of patients who may respond to therapies in clinically unmet disease classifications. Our agreement also lays the groundwork for a strong partnership in creating future companion diagnostics both inside and outside of oncology."